6533b853fe1ef96bd12ac1bf

RESEARCH PRODUCT

Result and cost of hepatic chemoembolisation with drug eluting beads in 21 patients.

C PernotPatrick HillonM.h. GuignardA. MusatSerge AhoMathieu BoulinL. VadotP. FagnoniBoris GuiuC. Malbranche

subject

Malemedicine.medical_specialtyCarcinoma HepatocellularHepatocellular carcinomaCostResultDrug Delivery SystemsTransarterial chemoembolisationOn demandmedicineHumansRadiology Nuclear Medicine and imagingIn patientChemoembolization TherapeuticAgedRetrospective StudiesAged 80 and overRadiological and Ultrasound TechnologyDrug eluting beadsbusiness.industryLiver NeoplasmsGeneral MedicineDirect costMiddle Agedmedicine.diseaseDrug eluting beadsMicrospheresSurgeryDiscontinuationTreatment OutcomeMedian timeHepatocellular carcinomaCosts and Cost AnalysisFemaleProspective payment systembusiness

description

Abstract Purpose The aim of our study was to assess the results and cost of a treatment strategy involving transarterial chemoembolisation with drug eluting beads (DEB-TACE) in patients with unresectable non-metastatic hepatocellular carcinoma (HCC). Patients and methods This study included all patients treated with DEB-TACE in our hospital between January 2009 and December 2010. All patients received DEB-TACE on demand and were evaluated after each session. Results Twenty-one patients received an average of 1.3 sessions. The median time to treatment discontinuation and median progression-free survival was 181 days and 295 days, respectively. Toxicity caused treatment discontinuation in three patients (14%). For the hospital, the average direct cost of treatment was €6,033 according to the analytical accounting system vs. €4,558 according to the official tariffs from the new French Diagnosis-Related Group prospective payment system ( P  = 0.002). Conclusion In the treatment of HCC, on-demand DEB-TACE stabilises the disease in some patients but has not yet been thoroughly evaluated.

yearjournalcountryeditionlanguage
2012-11-14Diagnostic and interventional imaging
10.1016/j.diii.2012.05.001https://pubmed.ncbi.nlm.nih.gov/23146417